Gilead Wins Reversal of $1.2B Patent Loss to Bristol-Myers: Bloomberg

by Vandana Singh, Benzinga Editor

August 26, 2021 12:58 PM | 1 min read |

Gilead Sciences Inc GILD persuaded a U.S. appeals court to reverse a $1.2 billion judgment Bristol-Myers Squibb & Co BMY had won over immuno-oncology treatments.
The patent owned by Bristol-Myers’s Juno Therapeutics and the Sloan Kettering Institute for Cancer Research is invalid, the U.S. Court of Appeals for the Federal Circuit ruled, Bloomberg reported.
The jury verdict that upheld the patent was “not supported by substantial evidence,” the three-judge panel ruled.
Price Action: GILD shares are up 0.37% at $71.68, and BMY shares are down 0.58% at $67.21 during the market session on the last check Thursday.

Posted In: Biotech News Health Care Legal General Briefs Immuno-oncology

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.